Syngene International Ltd. · NSE:SYNGENE
Syngene International — Investor Presentation (September 2025)
17 slides from Syngene International's investor presentation, Sep 9, 2025
Slide 1: Investor Presentation cover letter to stock exchanges
Ref: Syn/CS/SE/IP/2025-26/Sept/05 Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Karnataka, India. T +91 80 6891 8000 F +91 80 6891 8808 CIN: L85110KA1993PLC014937 www.syngeneintl.com September 09, 202
Slide 2: Unit-3 plant visit for Investors – 9th September 2025
Unit-3 plant visit for Investors – 9th September 2025
Slide 3: Agenda
Agenda Sr. no Timing Particulars Led by Deepak Jain (CFO) I 11:30 AM – 12:15 PM Tea + Brief Introduction (PPT) of the facility Himanshu Saxena (Head, Biologics manufacturing) Himanshu Saxena ( Head, Biologics manufacturing) Mr. Nainesh Dwivedi (Head, Quality for Unit-3) • Divide participant in 2 gro
Slide 4: Syngene Management & Leadership for Unit-3 visit
Syngene Management & Leadership for Unit-3 visit Himanshu Saxena Peter Bains Deepak Jain Head, Managing Director & CEO Chief Financial Officer Biologics Manufacturing • MD & CEO, Syngene International with over • CFO, Syngene International with over 25 years • Over two decades of expertise in supply
Slide 5: Introduction and overview of facility
01 Introduction and overview of facility Putting Science to Work Putting Science to Work
Slide 6: Background – acquired multimodal biologics facility from Stelis Biopharma
Background – acquired multimodal biologics facility from Stelis Biopharma with integrated drug substance and commercial DP capability in Dec 2023 Strengthens Syngene’s position in the fastest growing Why we acquired 250 segment of the global CRDMO market Market size* (USD bn) Immediate capacity addi
Slide 7: Guidance given at time of acquisition. We are maintaining the guidance for now
Guidance given at time of acquisition. We are maintaining the guidance for now Asset turnover of 1x in less than 5 years $75m acquisition price $10m modification capex (Acquisition concluded at gross value of Rs 617 (INR 100 Crores to repurpose and $85m to operationalise crores. Value buy as company
Slide 8: Current update and strategic focus
Current update and strategic focus - the facility was part capitalized in Q1 FY26. Focus is to drive integrated projects across human and animal health Where are we now Strategic focus Received local regulatory approvals in May 2025 Focus on building pipeline across human health and animal health Pa
Slide 9: Bird’s Eye View of Syngene Unit-3
Bird’s Eye View of Syngene Unit-3 Salient features of the multi modal facility comprising end to end DS and DP manufacturing capability • Drug Substance (DS) : • 8 KL (4*2 KL) commissioned • Feasibility for perfusion • Drug Product (DP) : • Commercial scale, high speed, fill-finish unit • 2 integrat
Slide 10: Integration Journey: Acquisition to Operation in 7 Months
Integration Journey: Acquisition to Operation in 7 Months Operations Q1 FY26 Production Part of Unit-3 facility became operational in Q1 FY26 Equipment July 2024 Delivered a GMP clinical batch Qualification and Area Qualification 15th July test batch initiated of drug substance for a US based Facili
Slide 11: Unit-3 (SU3) Site Master Plan
Unit – 3 (SU3) Site Master Plan Area Details ETP Plot area 22,000 m2 (5.4 Acres) Block-3 200L DS,DP, QC Block Name Utility Block -2 Block-2 2,000L DS + 2,000L DS Expansion Block 1 Expansion Area available 2 Floors (Ground Floor+ First Floor) Block 2 - DS Block First floor (2 wings of 10 KL capacity
Slide 12: Site visit to DS / Utilities
02 Site visit to DS / Utilities Putting Science to Work Putting Science to Work
Slide 13: Site visit – protocols
Site visit – protocols • Clothing: Minimum Gowning, Head cap & Shoe cover • Decorum to be maintained while visiting labs • Please limit Q&A with the technical teams related to infrastructure, technical/plant details etc. • We will have a separate Q&A/feedback session with Peter and Deepak to cover s
Slide 14: Lunch
03 Lunch Putting Science to Work Putting Science to Work
Slide 15: Feedback/Q&A
04 Feedback/Q&A Putting Science to Work Putting Science to Work
Slide 16: Feedback/ Q&A
Feedback/ Q&A • Feedback/thoughts on the site, capabilities, infrastructure from investors • Open Q&A Putting Science to Work 15
Slide 17: Thank you
Thank you © 2025 Syngene International Limited, Bengaluru, India. All Rights Reserved. Syngene believes the information in this document is accurate as of its publication date; such information is subject to change without notice. Syngene acknowledges the proprietary rights of other companies to the
Syngene International — Investor Presentation (September 2025) on 6ix